SCHEMBL641774

SCHEMBL641774

N/C(Cc1ccc(F)cc1Cl)=N\O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
L3MBTL1 Q9Y468 4/20 0.42
TDP1 Q9NUW8 1/20 0.40
TP53 P04637 1/20 0.39
ALOX15 P16050 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CRHBP P24387 1/20 0.38
CRHR2 Q13324 1/20 0.38
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MAPT P10636 2/20 0.37
MAPK1 P28482 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2C19 P33261 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL641775 1.00 LMNA (0.42) LMNASMN1; SMN2L3MBTL1TDP1TP53
SCHEMBL10264195 0.86 LMNA (0.46) LMNASMN1; SMN2L3MBTL1TDP1ALDH1A1
SCHEMBL837382 0.86 LMNA (0.46) LMNASMN1; SMN2L3MBTL1TDP1ALDH1A1
SCHEMBL2644244 0.82 L3MBTL1 (0.56) LMNAL3MBTL1TDP1TP53ALOX15
SCHEMBL2644247 0.82 L3MBTL1 (0.56) LMNAL3MBTL1TDP1TP53ALOX15
SCHEMBL21729219 0.82 IDO1 (0.47) LMNASMN1; SMN2ALDH1A1KDM4E
Hydrochloric Acid SCHEMBL11877107 0.81 L3MBTL1 (0.55) LMNAL3MBTL1TDP1TP53ALOX15
SCHEMBL1395757 0.79 ALDH1A1 (0.44) L3MBTL1ALOX15HSD17B10ALDH1A1MEN1
SCHEMBL836281 0.79 LMNA (0.49) LMNASMN1; SMN2ALDH1A1
SCHEMBL874094 0.79 LMNA (0.49) LMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS BREYE THERAPEUTICS APS (DK) 2020-02-20 US disclosed
EP-3215505-B1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE Bayer Pharma AG (DE) 2019-07-24 EP disclosed
US-10118930-B2 Piperidinylpyrazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-06 US disclosed
US-20170334917-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-11-23 US disclosed
US-8119663-B2 Heteroaryl-substituted piperidines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-02-21 US disclosed
EP-2227466-B1 HETEROARYL-SUBSTITUTED PIPERIDINES BAYER SCHERING PHARMA AG (DE) 2011-04-20 EP disclosed
US-20090306139-A1 HETEROARYL-SUBSTITUTED PIPERIDINES BAYER HEALTHCARE AG (DE) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055831-A1 HETEROCYCLIC P2X7 ANTAGONISTS P2RY1, P2RX1, P2RX3 LMNA 2079/4885SMN1; SMN2 2968/4885L3MBTL1 4468/4885
US-20090306139-A1 HETEROARYL-SUBSTITUTED PIPERIDINES VHL, PIGO, PLIN3 LMNA 217/4885SMN1; SMN2 3347/4885L3MBTL1 4330/4885
US-10118930-B2 Piperidinylpyrazolopyrimidinones and their use HAMP, SERPINC1, PRSS8 LMNA 2585/4885SMN1; SMN2 3486/4885L3MBTL1 4443/4885
US-20170334917-A1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE HAMP, SERPINC1, PRSS8 LMNA 2585/4885SMN1; SMN2 3486/4885L3MBTL1 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.